53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Ausborn, Natalie L ^a   Wang, Tong ^a   Wentz, Sabrina C ^a   Washington, Mary Kay ^a   Merchant, Nipun B ^a   Zhao, Zhiguo ^b   Shyr, Yu ^b   Chakravarthy, Anuradha Bapsi ^a   Xia, Fen ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

53BP1; BRCA1 protein; DNA damage; Pancreatic cancer; Repair

Indexed keywords

BINDING PROTEIN; CA 19-9 ANTIGEN; P53 BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; CA-19-9 ANTIGEN; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS;

EID: 84875294253     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-155     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jermal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Yeo CJ, Abrams RA, Grochow LB. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997, 225:621-633. 10.1097/00000658-199705000-00018, 1190807, 9193189.
3. Sohn TA, Yeo CJ, Cameron JL. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000, 4:567-579. 10.1016/S1091-255X(00)80105-5, 11307091.
4. Cameron JL, Pitt HA, Yeo CJ. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993, 217:430-438. 10.1097/00000658-199305010-00002, 1242815, 8098202.
5. Balcom JH, Rattner DW, Warshaw AL. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001, 136:391-398. 10.1001/archsurg.136.4.391, 11296108.
6. Birkmeyer JD, Finlayson SR, Tosteson AN. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery 1999, 125:250-256. 10.1016/S0039-6060(99)70234-5, 10076608.
7. Hsu CC, Herman JM, Corsini MM. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010, 17:981-990. 10.1245/s10434-009-0743-7, 2840672, 20087786.
8. Corsini MM, Miller RC, Haddock MG. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol 2008, 26:3511-3516. 10.1200/JCO.2007.15.8782, 18640932.
9. Klinkenbijl JH, Jeekel J, Sahmoud T. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776-782. 10.1097/00000658-199912000-00006, 1420941, 10615932.
10. Neoptolemos JP, Dunn JA, Stocken DD. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358:1576-1585. 10.1016/S0140-6736(01)06651-X, 11716884.
11. Neoptolemos JP, Stocken DD, Friess H. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210. 10.1056/NEJMoa032295, 15028824.
12. Wang B, Matsuoka S, Carpenter PB, Elledge S. 53BP1, a mediator of the DNA damage checkpoint. Science 2002, 298:1435-1438. 10.1126/science.1076182, 12364621.
13. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010, 11:196-207. 10.1038/nrm2851, 3261768, 20177395.
14. Xie A, Hartlerod A, Stucki M. Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair. Mol Cell 2007, 28:1045-1057. 10.1016/j.molcel.2007.12.005, 2275782, 18158901.
15. Banerjee S, Kaye S. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep 2011, 13:442-449. 10.1007/s11912-011-0193-9, 21913063.
16. Comen EA, Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer K 2010, 16:48-52.
17. Bunting SF, Callen E, Wong N. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010, 141:243-254. 10.1016/j.cell.2010.03.012, 2857570, 20362325.
18. Bouwman P, Aly A, Escandell JM. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010, 17:688-695. 10.1038/nsmb.1831, 2912507, 20453858.
19. Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual 2010, New York: Springer, 7.
20. Westra WH, Hruban RH, Phelps TH, Isacson C. Pancreas 2003, 88-92. New York: Springer, 2, Surgical Pathology Dissection: An Illustrated Guide.
21. College of American Pathologists Cancer Protocol for the examination of specimens from patients with carcinoma of the exocrine pancreas [http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/PancreasExo_11protocol.pdf], College of American Pathologists Cancer.
22. Karimi-Busheri F, Rasouli-Nia A, Mackey JR. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 2010, 12:R31. 10.1186/bcr2583, 2917024, 20525204.
23. Grotsky DA, Gonzalez-Suarez I, Novell A. BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells. J Cell Biol 2013, 200:187-202. Reference 23 in revised manuscript, 10.1083/jcb.201204053, 23337117.
24. Neboori HJR, Haffty BG, Wu H. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2012, 83:c677-c683.
25. R Development Core Team A language and environment for statistical computing 2011, Vienna, Austria: R Foundation for Statistical Computing, R Development Core Team.
26. Prados MD, Chang SM, Butowski N. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009, 27:579-584. 2645859, 19075262.
27. Smith RA, Bosonnet L, Ghaneh P. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 2008, 25:226-232. 10.1159/000140961, 18577869.
28. Kondo N, Murakami Y, Uemura K. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2010, 17:2321-2329. 10.1245/s10434-010-1033-0, 20336387.
29. Ikeda M, Okada S, Tokuuye K. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 2001, 91:490-495. 10.1002/1097-0142(20010201)91:3<490::AID-CNCR1027>3.0.CO;2-L, 11169931.
30. Micke O, Bruns F, Kurowski R. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 2003, 57:90-97. 10.1016/S0360-3016(03)00524-8, 12909220.
31. Saad ED, Machado MC, Wajsbrot D. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002, 32:35-41. 10.1385/IJGC:32:1:35, 12630768.
32. Berger AC, Sigurdson ER, LeVoyer T. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005, 23:8706-8712. 10.1200/JCO.2005.02.8852, 16314630.
33. Inoue K, Nakane Y, Iiyama H. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002, 9:27-34. 10.1245/aso.2002.9.1.27, 11829427.
34. Negi SS, Singh A, Chaudhary A. Lymph nodal involvement as prognostic factor in gallbladder cancer: location, count or ratio?. J Gastrointest Surg 2011, 15:1017-1025. 10.1007/s11605-011-1528-4, 21487831.
35. Nitti D, Marchet A, Olivieri M. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol 2003, 10:1077-1085. 10.1245/ASO.2003.03.520, 14597447.
36. Wijnhoven BP, Tran KT, Esterman A. An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg 2007, 245:717-725. 10.1097/01.sla.0000251703.35919.02, 1877056, 17457164.
37. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004, 70:235-240.
38. Pawlik TM, Gleisner AL, Cameron JL. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007, 141:610-618. 10.1016/j.surg.2006.12.013, 17462460.
39. Riediger H, Keck T, Wellner U. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009, 13:1337-1344. 10.1007/s11605-009-0919-2, 19418101.
40. House MG, Gonen M, Jarnagin WR. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 2007, 11:1549-1555. 10.1007/s11605-007-0243-7, 17786531.
41. Willett CG, Daly WJ, Warshaw AL. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 1996, 172:350-352. 10.1016/S0002-9610(97)89547-5, 8873528.
42. Abrams RA, Grochow LB, Chakravarthy A. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 1999, 44:1039-1046. 10.1016/S0360-3016(99)00107-8, 10421536.
43. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994, 69:515-519. 10.1038/bjc.1994.93, 1968879, 7510116.
44. Lai TC, Chow KC, Lin TY. Expression of 53BP1 as a cisplatin-resistant marker in patients with lung adenocarcinomas. Oncol Rep 2010, 24:321-328.